| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3292830 | Gastroenterology | 2014 | 12 Pages |
Abstract
In patients with moderate to severe UC, the addition of adalimumab to standard of care treatment reduced the number of hospitalizations for any cause, as well as for UC-related and UC- or drug-related complications, compared with placebo. ClinicalTrials.gov numbers, NCT00385736 and NCT00408629.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Brian G. Feagan, William J. Sandborn, Andreas Lazar, Roopal B. Thakkar, Bidan Huang, Nattanan Reilly, Naijun Chen, Mei Yang, Martha Skup, Parvez Mulani, Jingdong Chao,